Predicted protein targets (top 13)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | CTDSP1 | Q9GZU7 | 1/20 | 0.44 |
| ▸ | GPR84 | Q9NQS5 | 1/20 | 0.42 |
| ▸ | MAPT | P10636 | 1/20 | 0.42 |
| ▸ | CNR2 | P34972 | 1/20 | 0.41 |
| ▸ | SLC5A1 | P13866 | 1/20 | 0.40 |
| ▸ | SLC5A2 | P31639 | 1/20 | 0.40 |
| ▸ | KAT6A | Q92794 | 1/20 | 0.40 |
| ▸ | KMT2A | Q03164 | 2/20 | 0.40 |
| ▸ | MEN1 | O00255 | 1/20 | 0.40 |
| ▸ | ALDH1A1 | P00352 | 2/20 | 0.40 |
| ▸ | CYP1A2 | P05177 | 1/20 | 0.40 |
| ▸ | LMNA | P02545 | 1/20 | 0.38 |
| ▸ | POLB | P06746 | 1/20 | 0.38 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL7025423 | 0.92 | CTDSP1 (0.45) | CTDSP1GPR84MAPTCNR2SLC5A1 | |
| SCHEMBL10346035 | 0.88 | CTDSP1 (0.45) | CTDSP1MAPTKAT6AKMT2AMEN1 | |
| SCHEMBL10372347 | 0.86 | CALM1 (0.47) | MAPTKMT2AMEN1ALDH1A1LMNA | |
| SCHEMBL7029322 | 0.86 | DAO (0.40) | GPR84MAPTSLC5A1SLC5A2KMT2A | |
| SCHEMBL1180196 | 0.81 | GAA (0.41) | MAPTKMT2AMEN1ALDH1A1LMNA | |
| SCHEMBL30823619 | 0.81 | GAA (0.41) | MAPTKMT2AMEN1ALDH1A1LMNA | |
| SCHEMBL21465414 | 0.81 | PTGES2 (0.45) | MAPTCNR2KMT2AMEN1ALDH1A1 | |
| SCHEMBL1684413 | 0.81 | PTGES2 (0.45) | CTDSP1MAPTKMT2AMEN1ALDH1A1 | |
| SCHEMBL5189165 | 0.80 | TDP1 (0.45) | MAPTCNR2KMT2AMEN1ALDH1A1 | |
| SCHEMBL14324363 | 0.80 | PDIA6 (0.38) | KMT2A |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 3 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| EP-1042355-B1 | 11BETA-HALOGEN-7ALPHA-SUBSTITUTED ESTRATRIENES, METHOD FOR PRODUCING PHARMACEUTICAL PREPARATIONS CONTAINING SAID 11BETA-HALOGEN-7ALPHA-SUBSTITUTED ESTRATRIENES AND USE OF THE SAME FOR PRODUCING MEDICAMENTS | SCHERING AG (DE) | 2003-02-12 | — | — | EP | disclosed |
| EP-1042355-A1 | 11BETA-HALOGEN-7ALPHA-SUBSTITUTED ESTRATRIENES, METHOD FOR PRODUCING PHARMACEUTICAL PREPARATIONS CONTAINING SAID 11BETA-HALOGEN-7ALPHA-SUBSTITUTED ESTRATRIENES AND USE OF THE SAME FOR PRODUCING MEDICAMENTS | Schering Aktiengesellschaft (DE) | 2000-10-11 | — | — | EP | disclosed |
| WO-1999033855-A1 | 11β-HALOGEN-7α-SUBSTITUTED ESTRATRIENES, METHOD FOR PRODUCING PHARMACEUTICAL PREPARATIONS CONTAINING SAID 11β-HALOGEN-7α-SUBSTITUTED ESTRATRIENES AND USE OF THE SAME FOR PRODUCING MEDICAMENTS | SCHERING AKTIENGESELLSCHAFT (DE) | 1999-07-08 | — | — | WO | disclosed |